ImmVirX

ImmVirX is a company aimed at improving the prognosis of cancer patients. The company seeks to advance a new generation of cancer treatment by developing a novel oncolytic immunotherapy targeting cancer indications with high unmet needs. We are developing proprietary bi-selective RNA viruses that can selectively infect and kill cancer cells while inducing tumor inflammation and enabling immune cell infiltration, which may lead to specific innate and adaptive immune responses against cancer cells.